copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Home | GSK US Ben Schwartz, VP of Oncology, shares his 20-year GSK journey, from drug discovery to leading research Addressing Long-Standing Barriers to Adult Immunization Our COiMMUNITY Initiative fosters a systematic, collaborative, and approach to boost vaccinations
Contact us - GSK GSK US Response Center - (prescription products) Contact us online Disaster response - Contact our US Response Center online if you need help accessing your GSK medicines during a natural disaster
Careers | GSK US At GSK, we unite science, technology and talent to get ahead of disease together We aim to positively impact the health of 2 5 billion people by the end of the decade, as a successful, growing company where people can thrive
Products - GSK US In the US, if you are a patient and have questions about our medicines, please contact the GSK Response Center Our product areas Specialty medicines
Search jobs | GSK US Life at GSK We are transforming our culture to create an environment where individuals and teams are inspired to be ambitious for patients
Locations | GSK US Trade marks are owned by or licensed to the GSK group of companies GSK plc Registered in England and Wales No 3888792 Registered office: 79 New Oxford Street, London United Kingdom WC1A 1DG GSK websites; GSK Global website; Locations selector; Global Behind the science; GSKPro for HCPs; ViiV Healthcare;
GSK completes acquisition of TESARO, an oncology focused . . . GlaxoSmithKline plc (LSE NYSE: GSK) today announced that it has successfully completed the acquisition of TESARO, Inc an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5 1 billion (£4 0 billion)
Press releases - GSK US GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma Regulatory designation based on promising early data in this rare bone cancer
GSK and Flagship Pioneering partner to discover novel medicines and . . . GSK plc (LSE NYSE: GSK) and Flagship Pioneering (Flagship), the bioplatform innovation company, today announced they have entered a collaboration with the goal of discovering and developing a portfolio of future transformational medicines and vaccines, starting in respiratory and immunology